Senate Education hearing on assessments
Date Posted: 2/19/2013 | Author: Jennifer Mitchell, CAE
The Senate Education Committee is holding an informational hearing today on assessments. No specific testing bills are being heard, but the committee has invited various witnesses to discuss the testing issue. Throughout the day, committee members have raised questions about the number of tests administered, the differences between criterion-referenced tests and norm-referenced tests, the possibility of allowing teachers to see the tests that will be administered to their students, and the overall role of testing in the public education system. Earlier today, the committee voted to approve a substitute version of Senate Bill (SB) 3, which is Chairman Dan Patrick's bill pertaining to curriculum requirements for graduation. The bill requires the creation of personal graduation plans for all middle, junior high and high school students and steers them toward a single diploma under the "foundation high school program" (eliminating the current distinctions of the "minimum," "recommended" and "advanced" high school programs). The bill allows students who complete the foundation curriculum to take additional courses to earn endorsements in the areas of business and industry, STEM, arts and humanities or distinguished achievement. CSSB 3 (the committee substitute version of the bill) heads next to the Senate floor, where it is likely to be amended again. Read about ATPE's testimony last week on SB 3 here.
CONVERSATION
RECOMMENDED FOR YOU
05/01/2026
Teach the Vote’s Week in Review: May 1, 2026
Learn how the Department of Education’s proposed budget could impact Texas public education. Plus: ATPE’s Show Texas Teachers Love celebrates teachers throughout May.
05/01/2026
Secretary McMahon defends the Trump administration vision for dismantling the Department of Education
What does the FY 2027 Department of Education budget mean for Texas public schools?
05/01/2026
TRS Board of Trustees finalizes TRS-ActiveCare rates for 2026-27
TRS continues to outperform broader market trends, enabling reductions in some copays and coinsurance